Hills Bank & Trust Co Sells 229 Shares of Eli Lilly and Company (NYSE:LLY)

Hills Bank & Trust Co decreased its stake in shares of Eli Lilly and Company (NYSE:LLY) by 6.8% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 3,145 shares of the company’s stock after selling 229 shares during the quarter. Hills Bank & Trust Co’s holdings in Eli Lilly and Company were worth $1,833,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently made changes to their positions in the stock. Lipe & Dalton purchased a new stake in shares of Eli Lilly and Company in the fourth quarter worth approximately $26,000. Thompson Investment Management Inc. bought a new position in shares of Eli Lilly and Company during the 3rd quarter worth approximately $27,000. Optiver Holding B.V. purchased a new position in shares of Eli Lilly and Company in the 3rd quarter worth approximately $36,000. Family CFO Inc purchased a new stake in shares of Eli Lilly and Company during the third quarter valued at approximately $40,000. Finally, O Brien Wealth Partners LLC boosted its position in Eli Lilly and Company by 70.5% in the fourth quarter. O Brien Wealth Partners LLC now owns 75 shares of the company’s stock worth $44,000 after purchasing an additional 31 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Stock Performance

Shares of NYSE LLY traded down $7.81 during mid-day trading on Friday, hitting $763.74. The company had a trading volume of 983,953 shares, compared to its average volume of 3,047,955. Eli Lilly and Company has a 12 month low of $419.80 and a 12 month high of $800.78. The firm has a market cap of $725.86 billion, a P/E ratio of 113.12, a PEG ratio of 1.45 and a beta of 0.37. The company has a debt-to-equity ratio of 1.90, a current ratio of 1.35 and a quick ratio of 1.03. The business’s 50-day simple moving average is $761.92 and its 200-day simple moving average is $676.24.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Monday, May 6th. The company reported $2.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.53 by $0.05. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. The company had revenue of $8.77 billion for the quarter, compared to the consensus estimate of $8.94 billion. During the same period in the prior year, the company posted $1.62 EPS. The company’s revenue was up 26.0% compared to the same quarter last year. As a group, analysts predict that Eli Lilly and Company will post 13.82 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, June 10th. Stockholders of record on Thursday, May 16th will be paid a $1.30 dividend. The ex-dividend date is Wednesday, May 15th. This represents a $5.20 annualized dividend and a dividend yield of 0.68%. Eli Lilly and Company’s payout ratio is 76.58%.

Wall Street Analyst Weigh In

LLY has been the subject of a number of recent research reports. Erste Group Bank raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Wednesday, April 3rd. The Goldman Sachs Group raised their price objective on shares of Eli Lilly and Company from $650.00 to $723.00 and gave the stock a “neutral” rating in a report on Thursday, April 11th. DZ Bank cut shares of Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 target price on the stock. in a report on Wednesday, February 21st. Bank of America lifted their price target on Eli Lilly and Company from $800.00 to $1,000.00 and gave the company a “buy” rating in a research report on Friday, March 1st. Finally, Wells Fargo & Company raised their target price on Eli Lilly and Company from $700.00 to $825.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 6th. Three analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $757.95.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.